Skip to main content
Premium Trial:

Request an Annual Quote

Ameritox Licenses Ridge Diagnostics' Depression Biomarker Test

NEW YORK (GenomeWeb News) – San Diego-based Ridge Diagnostics today said that it has licensed exclusive rights to Ameritox to its MDDScore, a multiplex biomarker test for major depressive disorder.

Ameritox, a Baltimore-based specialized lab testing firm, also will make an undisclosed equity investment in Ridge and has committed to a next-stage clinical development program.

The MDDScore test measures 10 biomarkers associated with factors such as inflammation, development and maintenance of neurons, and interaction between brain structures involved in stress response and other biological functions, said Ridge. The test is designed to help physicians determine whether a patient has major depression and may help the physician in matching the proper treatment to the patient.

"Ameritox's investment in Ridge will likely accelerate the MDDScore test development and advance access to millions of patients already under the care of primary care and pain management physicians," Ridge Diagnostics CEO Lonna Williams said in a statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.